David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Antibody-drug conjugates are transforming NSCLC, but biomarkers remain the missing piece of the puzzle.
Targeting TROP2, New data/ICARUS-LUNG01 (Dato-DXd) and key biomarkers:
- Response: Associated with immune pathway activation, non-squamous NSCLC
- Resistance: Linked to low TROP2 cytoplasmic expression and DNA repair pathways
Thank you to the patients, families, investigators, and Daiichi-Sankyo who made ICARUS-LUNG01 possible!”
